Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2013. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by three franchises: urology-oncology, endocrinology and neurology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2012, R&D expenditure totaled close to €250 million, representing more than 20% of Group sales. The Group has close to 4,900 employees worldwide.
Established in Dublin in 1989, Ipsen Manufacturing Ireland Ltd is a specialised bulk Peptide Active Pharmaceutical Ingredient facility employing over 100 people. The plant supplies the active ingredient for two of the group’s major products.
Please enter your email address